Abstract:Objective: juvenile myelomonocytic leukemia (Juvenile myelomonocytic leukemia JMML) is a rare clonal disease of hematopoietic stem cells in young children. The response to chemotherapy is poor, the prognosis is poor, and a few patients can be relieved spontaneously. The level of methylation is closely related to the prognosis of JMML. In this study, the distribution characteristics and clinical indexes of JMML methylation were analyzed retrospectively. Methods: the newly diagnosed JMML from 2008.1 to 2022.11 in our center was selected as the research object. The samples were detected for DNA methylation and the clinical characteristics were analyzed. Results: methylation level was detected in 35 of 96 children with newly diagnosed JMML. The median age of onset was 27 months (3-82 months). There were 27 males and 8 females. The median platelet count was 70.6 × 109 × 10 ~ 9 × 10 ~ 9 × 10 ~ 9 / L, and the median absolute value of monocytes was 5.0 × 10 ~ 9 × 10 ~ 9 × 10 ~ 9 × 10 ~ 9 ml. All patients underwent JMML mutation and oral mucosal verification, including PTPN11 somatic mutation in 18 cases (51.4%), NRAS mutation in 10 cases (28.6%), KRAS mutation in 4 cases (11.4%), NF1 mutation in 7 cases (20%) and CBL mutation in 1 case (2.9%). Among them, 9 cases (25.7%) were compound mutations and 5 cases were recurrent mutations of PTPN11 and NF1. The DNA methylation level was divided into three subgroups: 4 cases (11.4%) hypomethylation (LM) group and 14 cases (40%) methylation group (IM) 17 cases (48.6%) hypermethylation (HM) group. Among the 17 patients in HM group, there were 7 cases of PTPN11 single mutation (41.2%) and 9 cases of compound mutation (52.9%), which were significantly higher than 3 cases of PTPN11 in IM group (21.4%). In IM group, simple NRAS or KRAS mutations accounted for 50%. The mutation distribution in LM group was 1 case of KRAS mutation, 2 cases of RANSBP2-ALK fusion gene and 1 case of no mutation. There were significant differences in age, platelet, fetal hemoglobin (HbF), PTPN11 mutation and ≥ 2 somatic mutation among different methylation subgroups (P < 0.05). The correlation analysis showed that methylation was positively correlated with 24 months of age, ≥ 33 × 10 9 mmol L, HbF, PTPN11 mutation and ≥ 2 somatic mutation (P < 0.05). Conclusion: high risk factors such as age at first diagnosis, PTPN11 mutation and compound mutation are significantly correlated with methylation in patients.

Report of two cases of juvenile myelomonocytic leukemia and review of literature

Analysis of Methylation Level and Clinical Characteristics of Juvenile Myelomonocytic Leukemia

Correlation Analysis of DNA Methylation Level and Clinical Characteristics in JMML Patients

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Impact of TET2, SRSF2, ASXL1 and SETBP1 Mutations on Survival of Patients with Chronic Myelomonocytic Leukemia.

Karyotypic Analysis and Prognosis for 41 Patients with Chronic Myelomonocytic Leukemia

Real‐world Data of Chronic Myelomonocytic Leukemia: A Chinese Single‐center Retrospective Study

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Interferon-gamma: pleiotropic effects on a rat pancreatic beta cell line.

Anti-inflammatory inflames Centocor's profits

Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases

Clinical feature of nucleophosmin 1 mutation in acute myelocytic leukemia children

Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia

Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World Experience

Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML)

Research of gene mutation in acute myeloid leukemia: development and prospect

Juvenile myelomonocytic leukemia with N-RAS and CBL mutations transformed to AML aggressively received haploidentical transplantation from her mother: a case report and literature review

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia